Vedolizumab treatment within 4 weeks of ileocolonic resection outperformed placebo in preventing postoperative endoscopic recurrence of Crohn’s disease in patients with at least one risk factor for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results